## ABBOTT LABORATORIES ISIN: US0028241000 WKN: 002824100



Asset Class: Stock

#### **Company Profile**

Abbott Laboratories engages in the discovery, development, manufacture, and sale of health care products. It operates through the following business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Medical Devices segment includes electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care products for people with diabetes, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.

### Financial figures, Fiscal year: from 01.01. to 31.12.

|                                | 0.04                                  |                | 201                                   | 20             | 200                                   | 24             |
|--------------------------------|---------------------------------------|----------------|---------------------------------------|----------------|---------------------------------------|----------------|
| Financial figures              | 2023<br>Assets Liabilities and equity |                | 2022<br>Assets Liabilities and equity |                | 2021<br>Assets Liabilities and equity |                |
| Current assets                 | 22,670,000,000                        |                | 25,224,000,000                        |                | 24,239,000,000                        |                |
| Common stock capital           |                                       | 24,869,000,000 |                                       | 24,709,000,000 |                                       | 24,470,000,000 |
| Fixed assets                   | 50,544,000,000                        |                | 49,214,000,000                        |                | 50,957,000,000                        |                |
| Equity capital of a company    |                                       | 38,827,000,000 |                                       | 36,905,000,000 |                                       | 36,024,000,000 |
| Cash and cash equivalents      | 6,896,000,000                         |                | 9,882,000,000                         |                | 9,799,000,000                         |                |
| Accrued liabilities            |                                       | 1,964,000,000  |                                       | 1,784,000,000  |                                       | 2,738,000,000  |
| Other assets                   | -                                     |                | -                                     |                | -                                     |                |
| Current liabilities            |                                       | 13,841,000,000 |                                       | 15,489,000,000 |                                       | 13,105,000,000 |
| Prepayments and accrued income | -                                     |                | -                                     |                | -                                     |                |
| Non-current liabilities        |                                       | 20,546,000,000 |                                       | 22,044,000,000 |                                       | 26,067,000,000 |
| Different income               |                                       | -              |                                       | -              |                                       | -              |
| Other liabilities              |                                       | 2,816,000,000  |                                       | 2,954,000,000  |                                       | 3,005,000,000  |
| Total assets                   | 73,214,000,000                        | 73,214,000,000 | 74,438,000,000                        | 74,438,000,000 | 75,196,000,000                        | 75,196,000,000 |

#### **Balance notes**

|                     | 2023    | 2022    | 2021    |
|---------------------|---------|---------|---------|
| Accounting standard | US-GAAP | US-GAAP | US-GAAP |
| Employees           | 114,000 | 115,000 | 113,000 |
| Equity ratio        | 53.34%  | 49.87%  | 48.20%  |
| Debt-equity ratio   | 87.48%  | 100.51% | 107.46% |

#### Others

|                  | 2023   | 2022   | 2021   |
|------------------|--------|--------|--------|
| Tax Expense Rate | 14.12% | 16.53% | 13.88% |

# **ABBOTT LABORATORIES**

| 131N. 030020241000 WINN. 002024100 ASSEt Class. Stock | ISIN: | US0028241000 | WKN: | 002824100 | Asset Class: | Stock |
|---|-------|--------------|------|-----------|--------------|-------|
|---|-------|--------------|------|-----------|--------------|-------|

# Income statement

|  | 2023           | 2022           | 2021           |
|--|----------------|----------------|----------------|
| Turnover   | 40,109,000,000 | 43,653,000,000 | 43,075,000,000 |
| Net income   | 5,701,000,000  | 6,905,000,000  | 7,042,000,000  |
| EBIT   | 6,519,308,800  | 7,884,467,200  | 8,015,283,200  |
| Operating income before taxes                                | 6,664,000,000  | 8,306,000,000  | 8,211,000,000  |
| Cash Flow  | 7,261,000,000  | 9,581,000,000  | 10,533,000,000 |
| Net interest income  | -313,000,000   | -132,000,000   | -367,000,000   |
| Research and development expenses                            | 2,719,000,000  | 2,852,000,000  | 2,738,000,000  |
| Income taxes   | 941,000,000    | 1,373,000,000  | 1,140,000,000  |
| Result from investments in subsidaries, associates and other | -              | -              | 0              |
| Revenues per employee  | 328,753        | 354,690        | 356,188        |

#### **Board of Directors**

# Members of Management Board

| Robert Alpern             | Member of Board of Directors  |
|---------------------------|-------------------------------|
| Sally Blount              | Member of Board of Directors  |
| Claire Babineaux-Fontenot | Member of Board of Directors  |
| Daniel Starks             | Member of Board of Directors  |
| Darren McDew              | Member of Board of Directors  |
| John Stratton             | Member of Board of Directors  |
| Michael O'Grady           | Member of Board of Directors  |
| Michael Roman             | Member of Board of Directors  |
| Michelle Kumbier          | Member of Board of Directors  |
| Nancy McKinstry           | Member of Board of Directors  |
| Paola Gonzalez            | Member of Board of Directors  |
| Robert B. Ford            | Chairman of Managing Board    |
| Andrea F. Wainer          | Member of Executive Committee |
| Daniel Salvadori          | Member of Executive Committee |
| Hubert L. Allen           | Member of Executive Committee |
| Lisa D. Earnhardt         | Member of Executive Committee |
| Mary K. Moreland          | Member of Executive Committee |
| Robert E. Funck, Jr.      | Member of Executive Committee |
|                           |                               |